Modified bloodroot compound shows promise against multidrug-resistant tuberculosis

FHS
October 8, 2024
11:50 pm

A modified compound taken from bloodroot, a wildflower native to North America, effectively fights multidrug-resistant tuberculosis (TB) bacteria in the test tube, according to a new study.

Vic Neufeld | Executive Chairman, Havn Life Sciences | Psychedelic Finance

You were on the ground floor of scaling up one of the largest cannabis companies on the planet. What similarities do you see from the

July 7, 2023

GSK to acquire Chimagen’s CMG1A46 for autoimmune treatment

The acquisition of CMG1A46 is a strategic move to address the diverse manifestations of lupus and the ongoing burden it places on patients. Credit: Indypendenz/Shutterstock.

October 30, 2024

Limited resources constrain federal oversight of medical device ads, GAO finds

Dive Brief: Federal agencies took 322 enforcement actions related to medical device advertising between 2018 and 2022, but their activities are constrained by resource limitations,

September 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.